THE EFFECTS OF THIOPHOSPHORIC ACID (UKRAIN) ON CERVICAL CANCER, STAGE IB BULKY
PENGSAA P.1, WONGPRATOOM W.2, VATANASAPT V.4*, UDOMTHAVORNSUK B.1, MAIRIENG E.3, TANGVORAPONGCHAI V.3, PESI M.3, KRUSAN S.3, BOONVISOOT V.3, NOWICKY J.W.5
1) Department of Obstectrics and Gynaecology, Faculty of
Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
2) Department of Clinical Immunology, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand.
3) Department of Radiology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
4) Cancer Unit, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
5) Ukrainian Anti-Cancer Institute, Margaretenstrasse 7, 1040 Vienna, Austria.
*Author to whom correspondence should be addressed.
Summary: This study was carried out to determine the clinical and immune response of a stage IB voluminous uterine cervical cancer to thiophosphoric acid alkaloid derivates from Chelidonium majus L. (Ukrain). The drugs were administered 10 mg intramuscularly every other day, for up to 10 injections. The two largest diameters and tumour volumes were measured and laboratory and immunological tests were performed before and after Ukrain administration. The patients were then operated on with type III Piver's radical hysterectomy. Three out of nine eligible cases had partial responses while six cases remained stable. Decreased total B lymphocytes and suppressor T lymphocytes were observed as well as increased total numbers of T lymphocytes and helper T lymphocytes. There was no single case of clinical or haematological toxicity apart from mild nausea. Two patients were treated with adjuvant radiotherapy due to lymphatic involvement and all nine patients were still alive at least six months after follow-up.